Home Business Australia Amplia gets nod for new cancer drug trial ahead of US push

Amplia gets nod for new cancer drug trial ahead of US push

3
0

Source : THE AGE NEWS

Biotech hopeful Amplia Therapeutics has been given the green light to begin its “ACCENT-Mini” clinical trial after receiving ethics approval to test its lead drug candidate, narmafotinib, alongside chemotherapy in patients with metastatic pancreatic cancer.

The approval is a critical milestone, allowing the company to start recruiting patients across three selected Australian clinical trial sites, where start-up activities are already well advanced. The ACCENT-Mini trial will evaluate a daily-dosed regimen of narmafotinib to determine the optimal safe and effective dosing rate.

Amplia Therapeutics is advancing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, with a particular focus on pancreatic cancer.

The new trial builds on encouraging data from Amplia’s previous ACCENT trial, which combined an intermittent dose of narmafotinib with standard chemotherapies gemcitabine and Abraxane. The study hit its primary target with a confirmed tumour response rate of 36 per cent, outperforming chemotherapy alone. It also delivered an encouraging complete response rate of 7.8 per cent and median overall survival of 11.1 months, without significantly altering the tolerability profile of chemotherapy.

Narmafotinib works by blocking a protein known as Focal Adhesion Kinase (FAK), which is found at unusually high levels in solid tumours such as pancreatic cancer. The protein contributes to the creation of dense, scar-like fibrotic tissue that forms a protective fortress around some tumours. By blocking FAK, Amplia believes narmafotinib can weaken this biological barrier, giving chemotherapy a cleaner shot at destroying the cancer cells within.

‘We believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes.’

Amplia Therapeutics chief executive officer and managing director Dr Chris Burns

Management says the safety and pharmacokinetic data, expected from the new study in late Q1 or early Q2 of 2027, will form a key part of its protocol submission to the US Food and Drug Administration (FDA) for a bigger registrational study of narmafotinib in pancreatic cancer.

Amplia Therapeutics chief executive officer and managing director Dr Chris Burns said: “We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options. Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini.”

The timing of ACCENT-Mini comes as pancreatic-cancer researchers increasingly focus on combination strategies to counter treatment resistance. The FDA recently approved a new KRAS-targeting drug that showed a significant survival benefit, highlighting the potential of this new class of therapies.

KRAS gene mutations are genetic changes that can cause cells to grow and divide uncontrollably, helping drive disease development. The gene normally acts like an on-off switch, controlling signals that tell cells when to grow. When mutated, the switch can become permanently stuck in the “on” position, encouraging cancer cells to multiply.

Notably, KRAS gene mutations are found in more than 90 per cent of pancreatic cancers, making them a major focus for drug developers. Amplia’s data suggests its FAK inhibitor narmafotinib could work alongside the KRAS drugs, potentially making it effective in a broader patient population or in powerful combination treatments.

With ethics approval now secured, the company has a clear path to continue building its case for its lead drug, narmafotinib. The data from this “mini” trial could have major implications for Amplia. If the daily dosing schedule proves safe and effective, it could provide the final piece of clinical evidence needed to design a pivotal study with the FDA. For a company tackling one of medicine’s most challenging cancers, the next results could pave the way towards commercial approval.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au